Analyst split weighs
The drop looks tied to diverging analyst views on Viking while pipeline updates keep attention on its Phase 3 studies.
Sources: https://www.boerse-global.de/viking-therapeutics-aktie-goldman-und-canaccord-ziehen-auseinander/839264, https://www.boerse-express.com/news/articles/viking-therapeutics-aktie-verlust-steigt-studien-kommen-voran, https://www.ad-hoc-
Previous verdicts for VKTX
- AI Search: Viking Therapeutics Rallies Sharply With No Clear Fresh Catalyst — 2026-11-09
- AI Search: Viking Therapeutics Rallies Against Market Selloff on Passive Stake — 2026-11-06
- AI Search: Viking Therapeutics Rallies Sharply as Squeeze Drives the Move — 2026-10-29
- AI Search: Viking Therapeutics Slips Modestly Amid Profit Taking — 2026-10-23
- VKTX gets UBS target — 2026-10-20
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works